Newsig · Seeking Alpha
Merck pulls BLA for antibody-drug conjugate I-DXd for small cell lung cancer
Market context: MRK: Merck is the company withdrawing the BLA for I-DXd. Pulling the BLA removes a potential revenue stream and signals a setback in its oncology pipeline.
Why it matters
MRK (Merck) · Why linked: Merck is the company withdrawing the BLA for I-DXd. Market context: Pulling the BLA removes a potential revenue stream and signals a setback in its oncology pipeline.
Reaction tracking
A completed 24-hour reaction record is not available for this story yet. Newsig only publishes measured price movement when the required market data is present.
Curated by Newsig — News in. Signal out.
How the reaction data is measured · Editorial policy